JP2025506173A - 自己免疫疾患の治療のためのインターロイキン－２ムテイン - Google Patents

自己免疫疾患の治療のためのインターロイキン－２ムテイン Download PDF

Info

Publication number
JP2025506173A
JP2025506173A JP2024547537A JP2024547537A JP2025506173A JP 2025506173 A JP2025506173 A JP 2025506173A JP 2024547537 A JP2024547537 A JP 2024547537A JP 2024547537 A JP2024547537 A JP 2024547537A JP 2025506173 A JP2025506173 A JP 2025506173A
Authority
JP
Japan
Prior art keywords
fold
seq
amino acid
agent
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506173A5 (https=
Inventor
アッシャー シャクター，
モヒット マトール，
デイビッド ウィリアム オルダッチ，
スーザン スローン，
ジル ヤーブロー，
ニコル アクラモフ，
ダイアン マ，
ウィリアム シー． タブス，
ミカエラ シュルツ，
Original Assignee
ビステラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ビステラ， インコーポレイテッド filed Critical ビステラ， インコーポレイテッド
Publication of JP2025506173A publication Critical patent/JP2025506173A/ja
Publication of JP2025506173A5 publication Critical patent/JP2025506173A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2024547537A 2022-02-11 2023-02-10 自己免疫疾患の治療のためのインターロイキン－２ムテイン Pending JP2025506173A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263309293P 2022-02-11 2022-02-11
US63/309,293 2022-02-11
PCT/US2023/062395 WO2023154870A1 (en) 2022-02-11 2023-02-10 Interleukin-2 muteins for the treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
JP2025506173A true JP2025506173A (ja) 2025-03-07
JP2025506173A5 JP2025506173A5 (https=) 2026-02-19

Family

ID=85476118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547537A Pending JP2025506173A (ja) 2022-02-11 2023-02-10 自己免疫疾患の治療のためのインターロイキン－２ムテイン

Country Status (10)

Country Link
US (1) US20230390360A1 (https=)
EP (1) EP4475875A1 (https=)
JP (1) JP2025506173A (https=)
KR (1) KR20240148001A (https=)
CN (2) CN119013034A (https=)
AU (1) AU2023219773A1 (https=)
CA (1) CA3243493A1 (https=)
MX (1) MX2024009868A (https=)
TW (1) TW202400218A (https=)
WO (1) WO2023154870A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
CN120346304A (zh) 2025-07-22
KR20240148001A (ko) 2024-10-10
AU2023219773A1 (en) 2024-08-01
US20230390360A1 (en) 2023-12-07
WO2023154870A1 (en) 2023-08-17
MX2024009868A (es) 2024-08-20
CA3243493A1 (en) 2023-08-17
TW202400218A (zh) 2024-01-01
EP4475875A1 (en) 2024-12-18
CN119013034A (zh) 2024-11-22

Similar Documents

Publication Publication Date Title
JP7483857B2 (ja) インターロイキン－２作用物質およびその使用
AU2002305716B8 (en) Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20240108690A1 (en) Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors
NZ576434A (en) Methods for treating immune disorders associated with graft transplantation with soluable CTLA4 mutant molecules
JP2024503506A (ja) インターロイキン－２変異体およびその使用
JP2025506173A (ja) 自己免疫疾患の治療のためのインターロイキン－２ムテイン
JP2024502708A (ja) インターロイキン－２作用物質を使用する方法
WO2021207274A2 (en) Human immune cells genomically modified to express orthogonal receptors
WO2015112904A1 (en) Socs mimetics for the treatment of diseases
HK40113125A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40124714A (zh) 用於治疗自身免疫性疾病的白细胞介素-2突变蛋白
HK40098728A (zh) 白介素-2突变体及其用途
CN116997351A (zh) 白介素-2突变体及其用途
CN116783213A (zh) Cd25偏向的抗il‐2抗体
CN111714618A (zh) T细胞和高亲和力pd-1融合蛋白的组合

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260210